Welcome to our dedicated page for Pharvaris N.V. news (Ticker: PHVS), a resource for investors and traders seeking the latest updates and insights on Pharvaris N.V. stock.
Pharvaris N.V. (PHVS) news centers on its progress as a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists for bradykinin-mediated angioedema. Company updates frequently highlight clinical milestones for its lead candidate deucrictibant, including pivotal Phase 3 programs in hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH).
Investors following PHVS news can expect detailed announcements on clinical trial results and timelines. Recent releases describe RAPIDe-3, a pivotal global Phase 3 study of deucrictibant immediate-release capsule for on-demand treatment of HAE attacks, which met its primary endpoint and all secondary efficacy endpoints with statistical significance and was reported as well tolerated. Other updates cover CHAPTER-3 and CHAPTER-4, Phase 3 studies of the extended-release tablet for long-term prophylaxis of HAE attacks, and CHAPTER-1 Phase 2 data showing sustained reductions in attack rates over long-term treatment.
Pharvaris news also includes information on the CREAATE Phase 3 study in AAE-C1INH, presentations of deucrictibant data at major medical congresses, and summaries of biomarker work such as the kinin assay being clinically validated to characterize bradykinin-mediated angioedema. Financial and corporate updates, including quarterly results, cash runway commentary, and details of public offerings of ordinary shares and pre-funded warrants, are furnished through press releases and Form 6-K filings.
For readers tracking PHVS, this news stream provides insight into the advancement of deucrictibant’s prophylactic and on-demand indications, regulatory filing plans such as the preparation of marketing authorization applications, and the company’s broader efforts in bradykinin-mediated diseases.
Pharvaris (Nasdaq: PHVS) announced the FDA's acceptance of its Investigational New Drug (IND) application for PHVS416, an oral bradykinin-B2-receptor antagonist aimed at treating hereditary angioedema (HAE). This milestone paves the way for a prophylactic study, complementing the ongoing Phase 2 clinical trial for on-demand treatment. PHVS416 offers a softgel formulation of the previously studied PHA121, which has shown promising results in earlier trials. Pharvaris aims to provide effective oral alternatives for HAE patients.
Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on oral bradykinin-B2-receptor antagonists for hereditary angioedema (HAE), announced CEO Berndt Modig's participation in BioCapital Europe. The event will feature a panel presentation titled “Shaping the New Biotech Reality – Key Lessons from COVID” on March 10, 2021, at 18:30 CET. Additionally, a corporate presentation will occur on March 11, 2021, at 14:50 CET. Both presentations will be accessible for 30 days on the Pharvaris website.
Pharvaris (Nasdaq: PHVS) has initiated the RAPIDe-1 Phase 2 study, dosing the first patient for its oral bradykinin B2 receptor antagonist, PHVS416, targeting hereditary angioedema (HAE) treatment. The trial will evaluate the efficacy, safety, and pharmacokinetics of PHVS416 in 54 adult patients with HAE type 1 or 2 across North America and Europe. The results aim to provide rapid and convenient on-demand treatment for HAE attacks, offering an alternative to injectable therapies. Pharvaris' approach could significantly enhance patient care for this rare condition.
Pharvaris (Nasdaq: PHVS) announced the presentation of clinical data for PHA121 at the 2021 AAAAI Virtual Annual Meeting. This single-dose treatment showed effective bradykinin inhibition in healthy volunteers, supporting initiation of studies in hereditary angioedema (HAE) patients this year. Results indicated that PHA121 achieves therapeutic levels quickly, with significant pharmacodynamic effects compared to icatibant. Adverse events were reported in 25% of subjects, consistent with placebo, and were mild or moderate. The company aims to develop both on-demand and prophylactic treatments using PHA121.
Pharvaris N.V. (Nasdaq: PHVS) has successfully closed its initial public offering, issuing 9,511,075 ordinary shares at $20.00 each, generating approximately $190.2 million in gross proceeds. This includes the full exercise of the underwriters' option to purchase an additional 1,240,575 shares. The shares commenced trading on February 5, 2021. Pharvaris focuses on developing small molecule bradykinin-B2-receptor antagonists for hereditary angioedema (HAE) and other related conditions, exemplifying its commitment to innovative therapeutic solutions.
Pharvaris N.V., a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 8,270,500 ordinary shares at $20.00 per share, totaling gross proceeds of approximately $165.4 million. The offering includes a 30-day over-allotment option for an additional 1,240,575 shares. Shares will trade on the Nasdaq under the symbol PHVS starting February 5, 2021. The offering aims to advance Pharvaris's development of oral bradykinin-B2-receptor antagonists for hereditary angioedema and other conditions.